Home News

ROVI completes the manufacture of the first batches of Moderna vaccine

Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological

Wed, 13/01/2021 - 17:03 0 min
Download related document
No votes yet
 
Related
ROVI reports operating revenue growth of 24% and EBITDA growth of 83%
Operating revenue increased by 24% to 270.8 million euros in the first nine months of 2019, mainly driven by the strength of the...
5 min
07/11/2019
ROVI announces the construction of a second heparin plant in Granada
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the future construction of a new manufacturing plant for the active substance...
3 min
05/09/2019
ROVI increases its operating revenue by 21% and EBITDA by 99%
Operating revenue increased by 21% to 177.5 million euros in the first half of 2019, mainly driven by the strength of the specialty...
6 min
30/07/2019